ReviewCurrent opinion in rheumatology2014
When and where does inflammation begin in rheumatoid arthritis?
Review in Current opinion in rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 170 citations in OpenAlex.
- Randomized, Double-Blind, Phase I Pharmacokinetic Study of Subcutaneous Recombinant Human Superoxide Dismutase (rhSOD) in Healthy Volunteers.Clinical pharmacokinetics · 2026Trial
- Preclinical Rheumatoid Arthritis: Pathogenesis, Risk Stratification, and Therapeutic Interception.Journal of clinical medicine · 2026Review
- Polysaccharides and Glycosides fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Zinc: a metallic shield against cardiac inflammation.Metallomics : integrated biometal science · 2026Review
- 10-HDA attenuates inflammatory responses in LPS-activated RAW264.7 cellsFrontiers in pharmacology · 2026Article
- Rheumatoid Lung Disease.Mediterranean journal of rheumatology · 2025Review
- Advances in the Medical Treatment of Rheumatoid Arthritis.Hand clinics · 2025Review
- Serum Concentrations of Interleukin-8 and Vitamin D Levels in Jordanian Patients with Rheumatoid Arthritis.Journal of inflammation research · 2025Article
- How to Distinguish Non-Inflammatory from Inflammatory Pain in RA?Current rheumatology reports · 2024Review
- Mecp2 promotes the anti-inflammatory effect of alpinetin via epigenetic modification crosstalk.Journal of cellular and molecular medicine · 2024Article
- Mesenchymal stem cell-derived extracellular vesicles: a regulator and carrier for targeting bone-related diseases.Cell death discovery · 2024Review
- Exposure to air pollutants and rheumatoid arthritis biomarkers: A scoping review.Seminars in arthritis and rheumatism · 2024Article
- Global, regional, and national burdens of rheumatoid arthritis in young adults from 1990 to 2019.Archives of medical science : AMS · 2024Article
- Retrospective analysis and preliminary laboratory validation of treatment efficacy and blood lipid levels in patients with rheumatoid arthritis.Clinical rheumatology · 2023Article
- Rheumatoid Arthritis Has Won the Battle but Not the War: How Many Joints Will We Save Tomorrow?Medicina (Kaunas, Lithuania) · 2023Review
- Advancement in nanotechnology for treatment of rheumatoid arthritis: scope and potential applications.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Clinically suspect arthralgia patients with a low educational attainment have an increased risk of developing inflammatory arthritis.Rheumatology (Oxford, England) · 2023Article
- Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury.Journal of biomedical science · 2023Article
- Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking.Annals of the rheumatic diseases · 2023Article
- Emerging role of mesenchymal stem/stromal cells (MSCs) and MSCs-derived exosomes in bone- and joint-associated musculoskeletal disorders: a new frontier.European journal of medical research · 2023Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe cause of rheumatoid arthritis (RA), as well as the timing and anatomic site at which RA-related autoimmunity is initiated, is currently unknown. An improved understanding of the initial steps in the development of RA would provide insights into disease pathogenesis that could ultimately lead to more effective treatments and/or novel preventive strategies in RA. RECENT
findingsSystemic inflammation and autoimmunity in RA begin long before the onset of detectable joint inflammation. Emerging data suggest that RA-related autoimmunity may be initiated at a mucosal site years before the onset of joint symptoms. The candidate sites of origin include the oral, lung and gastrointestinal mucosa, as data consistent with this hypothesis have been generated for each location. Individual patients may undergo initiation events at unique sites, but still converge on similar joint findings as the disease process evolves. SUMMARY: Investigations are needed to determine when and where RA begins, including comprehensive prospective studies of individuals in the preclinical period of RA that can provide insight into the relationship between mucosal inflammation, RA-related autoantibody generation and subsequent joint inflammation in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.